Industry News

19 December 2025

Pfizer & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India

Pfizer India and Cipla Limited announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.

18 December 2025

FDA approves RYBREVANT FASPRO™ : A first-of-its-kind subcutaneous therapy for EGFR-Mutated Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted approval to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), marking a significant advancement in the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer

16 December 2025

Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA is pleased to announce the upcoming launch1 of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial.

16 December 2025

Cipla launches Yurpeak (tirzepatide) for the treatment of Obesity and Type 2 Diabetes

Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak® — the second brand of Lilly’s tirzepatide in India, after Lilly received DCGI approval.

15 December 2025

Biocon Limited launches Liraglutide in the Netherlands

Biocon Limited an innovation-led global biopharmaceutical company, announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza®) and obesity (gSaxenda®), in the Netherlands through its distribution partner Pharmamedic B.V.

11 December 2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

Novo Nordisk and Akero Therapeutics Inc. announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.

11 December 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London.

10 December 2025

Amneal Receives USFDA approval for Albuterol Sulfate Inhalation Aerosol

Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Companys albuterol sulfate inhalation aerosol (90 mcg per actuation). The product is the generic equivalent of PROAIR® HFA (albuterol sulfate inhalation aerosol), a registered trademark of Teva Respiratory LLC.

4 December 2025

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

4 December 2025

Celltrion announces USFDA approval of 300mg strength of OMLYCLO® (omalizumab-igec)

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.

Search

Pfizer & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India

RECOMMENDED POSTS

Subscribe with us

Jobs by Category